These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12694322)

  • 21. Lipid abnormalities associated with end-stage renal disease.
    Liu J; Rosner MH
    Semin Dial; 2006; 19(1):32-40. PubMed ID: 16423180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid changes and statins in chronic renal insufficiency and dialysis.
    Wanner C; Krane V; Metzger T; Quaschning T
    J Nephrol; 2001; 14 Suppl 4():S76-80. PubMed ID: 11798151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Renal dyslipidemia in patients on chronic hemodialysis].
    Kovacić V; Sain M; Vukman V
    Lijec Vjesn; 2003; 125(3-4):77-80. PubMed ID: 12899098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of lipid-lowering dietary recommendations on the nutritional intake and lipid profiles of chronic peritoneal dialysis and hemodialysis patients.
    Saltissi D; Morgan C; Knight B; Chang W; Rigby R; Westhuyzen J
    Am J Kidney Dis; 2001 Jun; 37(6):1209-15. PubMed ID: 11382690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia.
    Shoji T; Hatsuda S; Tsuchikura S; Kimoto E; Kakiya R; Tahara H; Koyama H; Emoto M; Tabata T; Nishizawa Y
    Atherosclerosis; 2009 Dec; 207(2):579-84. PubMed ID: 19540497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.
    Dieplinger H; Schoenfeld PY; Fielding CJ
    J Clin Invest; 1986 Apr; 77(4):1071-83. PubMed ID: 3082933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid abnormalities in chronic renal failure, nephrotic syndrome and dialysis.
    Kes P
    Acta Med Croatica; 2001; 55(4-5):177-86. PubMed ID: 12398021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipoprotein structural abnormalities in chronic renal failure with and without hemodialysis.
    Camejo G; Riera G; Lee M; López F
    Biomed Biochim Acta; 1988; 47(3):239-45. PubMed ID: 3178789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lipid metabolism disorders in kidney failure].
    Romics L; Makó J
    Orv Hetil; 1978 Dec; 119(50):3055-8. PubMed ID: 215956
    [No Abstract]   [Full Text] [Related]  

  • 31. [Dyslipidemia in patients being treated with peritoneal dialysis].
    Zharfbin A
    Vnitr Lek; 2006 Nov; 52(11):1051-7. PubMed ID: 17165524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients.
    Wanner C; Zimmermann J; Quaschning T; Galle J
    Kidney Int Suppl; 1997 Nov; 62():S53-5. PubMed ID: 9350681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [When lipids increase in dialysis: the role of heparin! Standard heparin increases, low-molecular-weight heparin lowers triglycerides].
    Wiemer J; Scherberich JE
    MMW Fortschr Med; 1999 Oct; 141(43):29-32. PubMed ID: 10912118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lecithin: cholesterol acyltransfer, dyslipoproteinaemia and membrane lipids in uraemia.
    Gillett MP; Obineche EN; El-Rokhaimi M; Lakhani MS; Abdulle A; Sulaiman M
    J Nephrol; 2001; 14(6):472-80. PubMed ID: 11783603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoprotein metabolism in renal replacement therapy: a review.
    Kronenberg F; Dieplinger H; König P; Utermann G
    Isr J Med Sci; 1996 Jun; 32(6):371-89. PubMed ID: 8682643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
    Diepeveen SH; Verhoeven GW; Van Der Palen J; Dikkeschei LD; Van Tits LJ; Kolsters G; Offerman JJ; Bilo HJ; Stalenhoef AF
    J Intern Med; 2005 May; 257(5):438-45. PubMed ID: 15836660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lipid metabolism abnormalities and atherosclerosis in patients on maintenance hemodialysis].
    Musiał J; Undas A; Sysło K
    Przegl Lek; 1994; 51(6):264-7. PubMed ID: 7938663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased lipoprotein(a) concentrations in chronic renal failure.
    Haffner SM; Gruber KK; Aldrete G; Morales PA; Stern MP; Tuttle KR
    J Am Soc Nephrol; 1992 Nov; 3(5):1156-62. PubMed ID: 1482754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis.
    Prinsen BH; Rabelink TJ; Romijn JA; Bisschop PH; de Barse MM; de Boer J; van Haeften TW; Barrett PH; Berger R; de Sain-van der Velden MG
    Kidney Int; 2004 Mar; 65(3):1064-75. PubMed ID: 14871427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
    Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
    Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.